Academic literature on the topic 'Antifongiques azolés'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antifongiques azolés.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Antifongiques azolés"
Billaud, Eliane M. "Interactions métaboliques des antifongiques azolés." Journal de Mycologie Médicale 17, no. 3 (2007): 168–76. http://dx.doi.org/10.1016/j.mycmed.2007.05.004.
Full textPetitjean, O., A. Jacolot, and M. Tod. "Pharmacologie des antifongiques azolés systémiques." Médecine et Maladies Infectieuses 25 (November 1995): 14–26. http://dx.doi.org/10.1016/s0399-077x(05)81246-6.
Full textBleriot, J. P. "Candidoses systémiques et antifongiques azolés." Médecine et Maladies Infectieuses 25 (November 1995): 44–49. http://dx.doi.org/10.1016/s0399-077x(05)81250-8.
Full textRocchi, S., G. Reboux, and L. Millon. "Résistance aux antifongiques azolés d’origine environnementale : quelles alternatives pour l’avenir ?" Journal de Mycologie Médicale 25, no. 4 (2015): 249–56. http://dx.doi.org/10.1016/j.mycmed.2015.10.008.
Full textPanackal, A. A., J. L. Gribskov, J. F. Staab, K. A. Kirby, M. Rinaldi, and K. A. Marr. "Signification clinique de la résistance croisée aux antifongiques azolés chez Candida glabrata." Journal de Mycologie Médicale 17 (October 2007): S16—S21. http://dx.doi.org/10.1016/s1156-5233(07)80023-0.
Full textGaïes, E., I. Salouage, R. Sahnoun, et al. "Interaction médicamenteuse entre des antifongiques azolés et le tacrolimus chez quatre greffés rénaux." Journal de Mycologie Médicale 21, no. 1 (2011): 46–50. http://dx.doi.org/10.1016/j.mycmed.2010.11.003.
Full textNoël, T. "Le point sur les mécanismes de résistance aux antifongiques azolés chez les levures Candida." Journal de Mycologie Médicale 22, no. 1 (2012): 96. http://dx.doi.org/10.1016/j.mycmed.2011.12.003.
Full textJeanvoine, Audrey, Steffi Rocchi, Gabriel Reboux, et al. "Aspergillose sinusienne due à une souche d’ Aspergillus fumigatus TR34/L98H résistante aux antifongiques azolés chez un ouvrier du bois." Journal de Mycologie Médicale 25, no. 3 (2015): 240–41. http://dx.doi.org/10.1016/j.mycmed.2015.06.057.
Full textAlexandra, J. F., E. Pautas, I. Gouin-Thibault, A. Gouronnec, N. Le Strat, and V. Siguret. "Surdosages en AVK liés à la potentialisation de dérivés coumariniques par les antifongiques azolés utilisés par voie cutanée chez des patients âgés." La Revue de Médecine Interne 28 (June 2007): 61. http://dx.doi.org/10.1016/j.revmed.2007.03.087.
Full textLeport, C. "Thérapeutiques antifongiques azolées. Utilisation en clinique humaine." Médecine et Maladies Infectieuses 25 (November 1995): 74–75. http://dx.doi.org/10.1016/s0399-077x(05)81254-5.
Full textDissertations / Theses on the topic "Antifongiques azolés"
Schuster, Nathalie. "Les antifongiques azolés : utilisation dans le traitement des candidoses." Strasbourg 1, 1988. http://www.theses.fr/1988STR15068.
Full textPenaud, Jean-François. "Influence des lipides sur l'absorption des antifongiques azolés par voie orale." Paris 5, 1997. http://www.theses.fr/1997PA05P171.
Full textMorio, Florent. "Bases moléculaires de la résistance aux antifongiques azolés chez Candida albicans et Aspergillus fumigatus." Nantes, 2012. https://archive.bu.univ-nantes.fr/pollux/show/show?id=0e6955d3-3f11-4482-a1b6-273f6aca312e.
Full textCandida albicans and Aspergillus fumigatus are two fungal pathogens with a worldwide distribution and of medical importance, both being responsible for a wide range of diseases with a considerable medical and economic impact. Invasive infections are associated with a high mortality rate between 30 and 55 % and affect each year, nearly 500. 000 people worldwide. Azole antifungal agents are still considered as the drugs of choice for the management of these infections. However, azole resistance may occur, usually after long-term therapy and represent a major clinical issue due to the risk of treatment failure and because of the limited number of available drugs for the management of these infections. The investigation of the molecular basis of the mechanisms leading to azole antifungal resistance in C. Albicans and A. Fumigatus was the aim of our research project. All our data, lead us to identify new mutations involved in azole resistance including new mutations in CaERG11 and CaERG3, as well as of potential new gain-of-function mutations in the genes encoding the transcription factors Tac1, Mrr1 and Ucp2. These results also underline the remarkable diversity of the mechanisms that have been developed by these two major fungal pathogens to survive to antifungal pressure
Mattera, Agnès. "Pseudo-ictère et uvéite par interaction entre la rifabutine et les antifongiques azolés." Montpellier 1, 1996. http://www.theses.fr/1996MON11053.
Full textGuillon, Rémi. "Conception, synthèse et évaluation pharmacologique de nouveaux azolés à activité antifongique." Nantes, 2010. https://archive.bu.univ-nantes.fr/pollux/show/show?id=ab888df6-e7d8-486f-8cfe-7066e0125776.
Full textInvasive fungal infections are an increasing threat to human health. These infections predominantly occur in the context of increasingly aggressive immunosuppressive therapies. The overall mortality for invasive diseases caused by Candida spp. And Aspergillus spp. Is about 30-50, despite the advent of new diagnostic and therapeutic strategies. The search on new antifungal agents is mainly focused on the improvement of the antifungal spectrum, counteraction of resistance, reduction of toxicity and enhancement of bioavailability. Among the treatments, azoles act on the biosynthesis ofergosterol (major component of fungal membrane) by inhibiting P450-dependent lanosterol 14alpha-demethylase (CYP51),encoded by theeRG 11 gene. Previous researches in our laboratory have focused on inhibitors with 1-heteroaryl-2-phenyl-l-(17H-l,2,4-triazol-l-yl)propan-2-ol moiety. Those studies have resulted in isolation of compounds with potent activities against Candida albicans and an emergence of activity on Aspergillus fumigatus. On the basis of this study new azoles compounds (with indole, benzenesulfonamide or biaryle structure) were synthesized andevaluated in order to specify structure- activity relationships. In parallel, we synthesized analogues of albaconazole which is currently in phase III clinical trials, by introducing thiazoloquinazolinones via the Appel's salt chemistry
Brun, Sophie. "Résistance aux antifongiques azolés chez les mutants petite de candida glabrata : mécanismes et conséquences biologiques." Angers, 2005. http://www.theses.fr/2005ANGE0502.
Full textIn Candida glabrata, fluconazole exposure in vitro, but also in vivo, leads to the apparition of respiratory deficient (petite) mutants from mitochondrial origin associated with a resistance to azole antifungals and an increased susceptibility to polyenes. We showed that blockage of respiration induces azole resistance due to mitochondrial DNA deletions. This mechanism could explain the induction of petite mutations by azoles which have been demonstrated to inhibit the mitochondrial respiratory chain. Analysis of the mechanisms of azole resistance in C. Glabrata petite mutants, obtained by exposure to fluconazole or induced by ethidium bromide, showed an increased expression of the genes CgCDR1 and CgCDR2 encoding the ATP-binding cassette efflux pumps, but no alteration of the gene CgERG11 encoding the azole target. Moreover, sterol analysis of these petite mutants revealed an absence of esterification and a marked augmentation in free ergosterol content which can explain their increased susceptibility to polyenes. Finally, despite the overexpression in these mutants of the gene CgEPA1 encoding an adhesin, their adherence capacities are not significantly modified and their virulence in mice is drastically decreased compared with parent isolates. This suggests that the apparition in vivo in C. Glabrata of azole resistant petite mutants could be disregarded clinically
Eiden, Céline. "Essai de faisabilité du suivi thérapeutique pharmacologique et de l'optimisation des antifongiques azolés récents : voriconazole et posaconazole." Montpellier 1, 2009. http://www.theses.fr/2009MON13508.
Full textBerge, Maud. "Bases pharmacologiques de la manipulation des antifongiques azolés (voriconazole, posaconazole) chez les patients transplantés pulmonaires porteurs de mucoviscidose." Paris 5, 2010. http://www.theses.fr/2010PA05P635.
Full textInvasive aspergillosis is an emerging problem in immunocompromised patients with a poor prognosis and is particularly serious in patients with cystic fibrosis undergoing lung transplantation (CFLTx). Today the antifungal therapeutic arsenal offers several possibilities for long term oral therapy including azole drugs: voriconazole (VRZ) and posaconazole (PSZ). VRZ is extensively metabolized by the cytochrome isoenzymes (CYP), mainly CYP2C19, and to a lesser extend, CYP3A4 and CYP2C9. VRZ and PSZ are known to be potent inhibitors of CYP3A4 resulting in drug drug interactions (DDI). Targets for such DDI are numerous, but immunosuppressive drugs (IS) are of major concern. The aim of this study is to explore the variability of VRZ and PSZ exposure in CFLTx patients. 53 patients received VRZ (n = 35) and PSZ (n = 17). Analysis of trough concentrations (C0) shows subtherapeutic levels with VRZ (30%) and PSZ (65%) justifying the use of high doses (respectively 43%, p <0. 01 and 35% p <0. 0001). Carriers of the CYP2C19*2 deficient allele require standard VRZ doses but exhibit a higher variability compared with wild type. Quantitative DDI analysis shows that tacrolimus (IS) dose should be decreased by factors of 3 and 4 respectively with PSZ and VRZ. The risk of long underdosed periods, frequently addressed in this population, could justify, on a pharmacokinetic (PK) basis, the need for combination with an exclusive parenteral antifungal while waiting for azole relevant drug level. High PK variability, the risk of low exposure, therapeutic issues and DDI management in CF disease justify close monitoring with systematic combined therapeutic drug monitoring of azole and IS
Bart-Delabesse, Emmanuelle. "Septicémies candidosiques dans un centre de brûlés : typage moléculaire et sensibilité aux antifongiques azolés des souches de "Candida albicans" et de "Candida parapsilosis"." Paris 5, 1994. http://www.theses.fr/1994PA05P187.
Full textReisser, Cyrielle. "Analyse de la variabilité intraspécifique chez les levures : résistance à l'ammonium et aux composés azolés." Thesis, Strasbourg, 2014. http://www.theses.fr/2014STRAJ012/document.
Full textIn all species, mutations and chromosomal rearrangements are drivers of genomes evolution. These processes generate the genetic diversity at the origin of the phenotypic variations observed between the individuals of the same species. This variation is essential for their adaptation to a new environment. The yeasts are isolated from various ecological and geographical niches and show an important phenotypic variation. According to these characteristics, they are excellent modelorganisms to determine the genetic origins of the observed phenotypic variation. In this context, the study focused on the variation of resistance to ammonium and azole antifungals within two yeast species: Saccharomyces cerevisiae and Lachancea kluyveri. The analyses of the genetic origin of the resistance to these compounds show that this genetic variation could occur at several levels: coding sequence for resistance to ammonium and regulatory sequence for resistance to antifungal agents. In addition, evolving experiments have showed that the adaptation to a new environment was done by gene dosage, through the acquisition of extrachromosomes in both species studied
Book chapters on the topic "Antifongiques azolés"
Schrapp, Aurélien, and Fabien Lamoureux. "Antifongiques azolés." In Pharmacologie des Anti-Infectieux. Elsevier, 2018. http://dx.doi.org/10.1016/b978-2-294-75300-8.00014-8.
Full text